CB₁ cannabinoid receptor antagonism for treating inflammation and arthritis

Bibliography

• HOWLETT AC, BREIVOGEL CS, CHILDERS SR, DEADWYLER SA, HAMPSON RE, PORRINO LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology (2004) 47(Suppl. 1):345-358.
   PubMed Web of Science ®Google Scholar
• LAMBERT DM, FOWLER CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. (2005) 48:5059-5087.
   PubMed Web of Science ®Google Scholar
• LANGE JHM, KRUSE CG: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
   PubMed Web of Science ®Google Scholar
• MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. (2005) 12:1361-1394.
   PubMed Web of Science ®Google Scholar
• MUCCIOLI GG, LAMBERT DM: Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Patents (2006) 16:1405-1423.
   Web of Science ®Google Scholar
• MACKIE K: Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. (2005) 299-325.
   PubMedGoogle Scholar
• MACKIE K: Cannabinoid receptors as therapeutic targets. Ann. Rev. Pharmacol. Toxicol. (2006) 46:101-122.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacologic. Rev. (2002) 54:161-202.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-592.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
   PubMed Web of Science ®Google Scholar
• HENNESS S, ROBINSON DM, LYSENG-WILLIAMSON KA: Rimonabant. Drugs (2006) 66:2109-2119.
   PubMed Web of Science ®Google Scholar
• BIFULCO M, GRIMALDI C, GAZZERRO P, PISANTI S, SANTORO A: Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol. (2007) 71:1445-1456.
   PubMed Web of Science ®Google Scholar
• PATEL PN, PATHAK R: Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am. J. Health Syst. Pharm. (2007) 64:481-489.
   PubMed Web of Science ®Google Scholar
• LAFONTAN M, PIAZZA PV, GIRARD J: Effects of CB1 antagonist on the control of metabolic functions in obese Type 2 diabetic patients. Diabetes Metab. (2007) 33:85-95.
   PubMedGoogle Scholar
• LE FOLL B, GOLDBERG SR: Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. (2005) 312:875-883.
   PubMedGoogle Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ, FINER N, HOLLANDER P, JENSEN MD, VAN GAAL LF: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet (2006) 368:1660-1672.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA-CLERC F, JULIEN B, GRENARD P et al.: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. (2006) 12:671-676.
   PubMedGoogle Scholar
• RACHELEFSKY GS, OPELZ G, MICKEY MR et al.: Intact humoral and cell-mediated immunity in chronic marijuana smoking. J. Allergy Clin. Immunol. (1976) 58:483-490.
   PubMed Web of Science ®Google Scholar
• CROXFORD JL, YAMAMURA T: Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. (2005) 166:3-18.
   PubMed Web of Science ®Google Scholar
• VALENZANO KJ, TAFESSE L, LEE G et al.: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48:658-672.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ T, FARTHING JN, ZVONOK AM, MAKRIYANNIS A, HOHMANN AG: Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br. J. Pharmacol. (2007) 150:153-163.
   PubMed Web of Science ®Google Scholar
• GUINDON J, DESROCHES J, BEAULIEU P: The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br. J. Pharmacol. (2007) 150:693-701.
   PubMedGoogle Scholar
• ROMERO-SANDOVAL A, EISENACH JC: Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology (2007) 106:787-794.
   PubMedGoogle Scholar
• WHITESIDE GT, LEE GP, VALENZANO KJ: The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr. Med. Chem. (2007) 14:917-936.
   PubMed Web of Science ®Google Scholar
• GIBLIN GM, O'SHAUGHNESSY CT, NAYLOR A et al.: Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the ttreatment of inflammatory pain. J. Med. Chem. (2007) 50:2597-2600.
   PubMed Web of Science ®Google Scholar
• CROCI T, ZARINI E: Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br. J. Pharmacol. (2007) 150:559-566.
   PubMed Web of Science ®Google Scholar
• COSTA B: Rimonabant: more than an anti-obesity drug? Br. J. Pharmacol. (2007) 150:535-537.
   PubMed Web of Science ®Google Scholar
• PETROSINO S, PALAZZO E, DE N V et al.: Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2007) 52:415-422.
   PubMed Web of Science ®Google Scholar